{
    "nctId": "NCT02445586",
    "briefTitle": "Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer",
    "officialTitle": "A Phase IV, Multicenter, Open-Label, Single-Arm Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in First Line Treatment of Indian Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly-effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by the participant and/or partner\n* Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection; participants with measurable and/or non-measurable disease are eligible\n* Known and documented HER2-positive\n* Known and documented LVEF of at least 50 percent (%)\n* Adequate organ function\n* A negative serum beta-human chorionic gonadotropin (beta-HCG) test for women of childbearing potential (premenopausal, or less than \\[\\<\\] 12 months of amenorrhea post-menopause, and women who have not undergone surgical sterilization \\[absence of ovaries and/or uterus\\]) within 7 days prior to the first dose of study treatment with the result available prior to first dosing\n\nExclusion Criteria:\n\n* Previous systemic non-hormonal anti-cancer therapy for the metastatic or locally recurrent disease\n* Pregnant or lactating women\n* Current clinical or radiographic evidence of central nervous system (CNS) metastases\n* Disease progression while receiving or within 12 months of completion of trastuzumab and/or lapatinib treatment in the adjuvant or neo-adjuvant setting\n* History of LVEF decline to below 50% during or after prior trastuzumab adjuvant or neo-adjuvant therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}